Flyte Aviation (NYSE: VJET) launched Flyte Club, a prepaid private aviation program offering fixed-price trip packages with savings up to 30%. Customers buy 10, 20 or 30 one-way flights at discounts of 10%, 20% or 30%, respectively, off applicable one-way retail rates. Each credit covers the customer's entire party on an eligible route; departures remain subject to availability and confirmation.
On an example route priced at $4,900 retail, the 30-trip package costs $102,900, versus $147,000 in combined retail value. Cash is collected at package purchase, ahead of flights. Flyte aims to increase repeat bookings and improve aircraft utilization through earlier visibility into recurring demand. Its technology roadmap plans to connect package purchasing, flight requests and credit tracking through one account.
Flyte Aviation (NYSE American: VJET) signed a non-binding letter of intent to sell its legacy cardiology assets, targeting year-end 2026 closing. The proposed sale covers subsidiary Catheter Precision's VIVO, LockeT and associated life sciences assets. It contemplates cash at closing, subject to adjustments, escrow and indemnification provisions, plus potential contingent payments tied to future monetization events or value thresholds within six years after closing.
Flyte expects the sale to complete its transition to private aviation, reduce operating expenses and fund fleet expansion and growth initiatives. Completion requires due diligence, a definitive agreement, board and any required stockholder or other approvals, and third-party consents. Preliminary, unaudited third-quarter 2026 revenue was approximately $2.1 million, up 110% quarter over quarter.
Flyte Aviation (VJET) subsidiary Catheter Precision received FDA 510(k) clearance expanding the patient population covered by its VIVO system’s labeling. The expanded Indications for Use includes patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia, a heart rhythm disorder. Structural heart disease involves damaged, scarred, or enlarged heart tissue that disrupts the heart’s electrical pathways.
Catheter Precision said its clinical data demonstrates that VIVO maintains the same accuracy and safety standards in patients with structural heart disease as in those without it. The company also said visualizing patient-specific anatomy before ablation supports planning and can reduce procedure times and improve patient outcomes.
Flyte Aviation (VJET) has received Transport Canada approval to commence flights into and out of Canada, expanding its international reach. The approval adds Canada to a network that already includes Caribbean destinations. Flyte initially expects to connect northern and northeastern U.S. urban areas with Toronto, Montreal and Ottawa, subject to applicable airport, customs and operational requirements.
Flyte also reported estimated, preliminary third-quarter 2026 revenue of approximately $2.1 million, representing 110% quarter-over-quarter growth. Since launching its direct-to-consumer booking platform in late May, it has added more than 13,000 registered accounts, bringing its total platform user base to more than 20,000 users.
Flyte Aviation (VJET) intends to double its Vision Jet fleet to ten aircraft in the first quarter of 2027. The company currently operates five Vision Jets and plans to increase the fleet to eight, with an intention to reach ten in that quarter.
Flyte also plans to begin California service in the first quarter of 2027. Its current footprint extends along the East Coast, with international service to Canada and the Bahamas. The company expects the planned fleet expansion to increase revenue, aircraft availability and regional coverage. The plans accompanied Flyte's congratulations to Cirrus Aircraft on the Vision Jet's tenth anniversary and more than 800 deliveries worldwide.
Catheter Precision, a wholly owned subsidiary of Flyte Aviation (VJET), announced publication of a comparative study evaluating its LockeT device.
The 172-patient, peer-reviewed study compared LockeT with Abbott’s Perclose after large bore venous access for electrophysiologic procedures. Published in The Journal of Interventional Cardiology, it reported cumulative access-site complications of 1.2% with LockeT versus 9.3% with Perclose. Device failure rates were 0.0% versus 4.7%, respectively. Both methods produced similar times to hemostasis, or stopping bleeding, and similar rates of same-day patient discharge.
Flyte Aviation (NYSE American: VJET) has launched its Partner Portal, establishing a dedicated business-to-business distribution channel for private aviation bookings. The platform gives partner organizations dedicated accounts, digital booking access and exclusive preferred partner pricing. It builds on relationships developed during 2026 across hospitality, sports, entertainment and luxury lifestyle.
Since its direct-to-consumer platform launched in late May, Flyte has added more than 13,000 registered accounts, bringing its platform user base to more than 20,000. Previously reported preliminary third-quarter 2026 revenue was approximately $2.1 million, up 110% quarter over quarter; direct-to-consumer revenue exceeded $500,000. Flyte expects the partner model to support additional flight volume, customer acquisition, repeat bookings and higher aircraft utilization as its network expands.
Flyte Aviation (VJET) signed an exclusive multi-year partnership naming it the Official Private Aviation Partner of the Philadelphia 76ers.
The companies expect to collaborate on digital and social media, premium hospitality, fan engagement and private aviation experiences. Flyte will have opportunities to introduce its platform to fans, season-ticket members, premium customers and corporate partners. They also plan to explore in-arena promotions, including a proposed “Halftime Flyte Challenge” offering selected fans a chance to win a private flight by making a half-court shot.
Flyte Aviation (VJET) reported preliminary third-quarter 2026 revenue of approximately $2.15 million, up approximately 110% from the second quarter.
Revenue compared with $1.02 million in Q2 2026. Aviation revenue rose 150% sequentially to approximately $1.87 million. MedTech revenue reached approximately $280,000, up 24% year over year and 4% sequentially. Direct-to-consumer revenue surpassed $500,000 during Q3. Since the booking platform's redesign in late May 2026, more than 13,000 accounts have been added, lifting registered users 185% to more than 20,000.
Flyte is adding aircraft and expects them to support revenue growth during the current quarter and into 2027. Caribbean operations have begun; permitting for flights to and within Canada is nearly finished. The financial results are preliminary and unaudited and may change.
Flyte Aviation (NYSE American: VJET) changed its corporate name from Catheter Precision and its ticker from VTAK, effective October 5, 2026. The rebranding marks a repositioning around private aviation and its AI-driven booking platform.
Flyte plans to expand its customer network, aircraft fleet and geographic reach. During fourth-quarter 2026, it plans to invest in website and mobile application development, AI data analytics and customer acquisition. Its longer-term strategy includes connecting participants across North American private aviation, with potential acquisitions and technology development among its growth options.
Flyte says its Life Sciences operations will not be capital constrained or downsized as it directs capital toward aviation growth. It also commits to continued funding of multiple ongoing research trials and studies.